Gibson's apology: a eulogy for Chris - New Times San Luis Obispo
A SLO philosopher's uncompromising life compels us to examine our own
www.newtimesslo.comHere’s the latest I can share based on recent public reporting.
-
Chris Gibson (the entrepreneur behind Recursion Pharmaceuticals) is in the news for leadership changes at Recursion. Reports indicate he announced he would not seek re-election to Recursion’s board and would transition to an advisory role, with the board term continuing through June 2026. This marks a significant governance moment for the company and for Gibson’s ongoing involvement.[2]
-
Other mentions of Chris Gibson in 2025–2026 include profiles and coverage that describe his tenure as Recursion CEO, including milestones like the IPO, the strategic merger, and later efforts to streamline the pipeline and workforce to extend cash runway during tougher periods. Those pieces frame Gibson as a prominent figure in the AI-driven biotech space.[1]
-
There are unrelated or similarly named individuals with the same name in different contexts (sports stats pages, regional writers, etc.), but the current major English-language business news focus is on Gibson’s near-term board advisory role at Recursion and his stepping back from day-to-day leadership duties.[2]
Would you like a concise timeline of Chris Gibson’s governance changes at Recursion with dates, or a set of links to primary sources for deeper reading? I can also summarize the implications for Recursion’s strategy and funding if that’s useful. I can provide up-to-date citations after each sentence if you want strict sourcing.